Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multi-Center, Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Clinical Study to Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD

NCT02450890 is registered in ClinicalTrials.gov with Orient Pharma Co., Ltd. as lead sponsor.

NCT NCT02450890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02450890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multi-Center, Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Clinical Study to Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD
Lead sponsor
Orient Pharma Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2015
Completion date
February 28, 2017
Enrollment
114 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder